<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>semaglutide access &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/semaglutide-access/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 21 Jan 2025 16:56:53 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>semaglutide access &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Exploring the Influencing Factors for Semaglutide Initiation in Adults Struggling with Obesity</title>
		<link>https://bioengineer.org/exploring-the-influencing-factors-for-semaglutide-initiation-in-adults-struggling-with-obesity/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 21 Jan 2025 16:56:53 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[health equity]]></category>
		<category><![CDATA[insurance coverage disparities]]></category>
		<category><![CDATA[obesity treatment barriers]]></category>
		<category><![CDATA[semaglutide access]]></category>
		<category><![CDATA[systemic healthcare inequities]]></category>
		<guid isPermaLink="false">https://bioengineer.org/exploring-the-influencing-factors-for-semaglutide-initiation-in-adults-struggling-with-obesity/</guid>

					<description><![CDATA[Recent research published in JAMA Network Open highlights pivotal trends affecting access to semaglutide, a groundbreaking glucagon-like peptide-1 (GLP-1) receptor agonist, among individuals without diabetes. This cohort study meticulously examined the interplay of sociodemographic variables, healthcare dynamics, and clinical factors that may shape treatment accessibility for obesity. The study casts a spotlight on the often-overlooked [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">234353</post-id>	</item>
	</channel>
</rss>
